Sjoerd Van Der BurgSjoerd Van Der Burg, PhD, is Head of Experimental Cancer Immunology and Therapy Institute and of Research Laboratories Medical Oncology, Department of Medical Oncology, at Leiden University Medical Center, in The Netherlands. His primary interest is he exploration of key factors in host-tumor interactions that determine successes and failures in the immunotherapy of cancer. Dr. Van Der Burg co-developed the synthetic long peptide vaccine concept, in particular for HPV-induced cancers and currently is developing a vaccine to stimulate the immune response to TAP-deficient tumors.Sjoerd Van Der Burg, PhD, is Head of Experimental Cancer Immunology and Therapy Institute and of Research Laboratories Medical Oncology, Department of Medical Oncology, at Leiden University Medical Center, in The Netherlands. His primary interest is the exploration of key factors in host-tumor interactions that determine successes and failures in the immunotherapy of cancer. Dr. Van Der Burg co-developed the synthetic long peptide vaccine concept, in particular for HPV-induced cancers and currently is developing a vaccine to stimulate the immune response to TAP-deficient tumors. Read More Read Less